The UMB Digital Archive is getting an upgrade! The upgrade requires a content freeze starting 1/27/25 and is expected to last two weeks. Any new user accounts or submissions made to the Archive during this time will not be transferred to the upgraded site. Contact ArchiveHelp@hshsl.umaryland.edu for questions.

Show simple item record

dc.contributor.authorHesselgrave, Natalie
dc.date.accessioned2021-02-05T16:24:20Z
dc.date.available2021-02-05T16:24:20Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/10713/14474
dc.descriptionPhysiology
dc.descriptionUniversity of Maryland, Baltimore
dc.descriptionPh.D.
dc.description.abstractMajor depressive disorder (MDD) is a leading cause of mental illness world-wide. Economists estimate MDD to be one of the leading causes of disability worldwide. The cost is not just due to treatment, but comorbidities, lost work and suicide, too. However, treatments are available and range from psychotherapy, pharmacotherapy or more invasive treatments like electroconvulsive therapy or deep brain stimulation. For decades, the standard of pharmacotherapy care has been selective serotonin reuptake inhibitors (SSRIs). Yet, SSRIs are only effective in 60% of MDD patients and require weeks of treatment before reaching therapeutic efficacy. Thus, a large proportion of individuals experiencing MDD endure symptoms for weeks without guaranteed relief. In 2000, low doses of ketamine, a dissociative anesthetic, was found to have rapid acting antidepressant effects. Prior to this, electroconvulsive therapy was the only treatment known to induce rapid antidepressant effects. The use of ketamine as an antidepressant has been met with resistance since it is a known drug of abuse, has an addictive potential and psychotomimetic side effects. Findings from recent human studies suggest a single oral administration of psilocybin has antidepressant effects within 7 days. However, the hallucinatory effects of psilocybin, like ketamine, severely limit its clinical use. Currently, psilocybin is administered in a controlled environment with psychological support, which greatly increases the cost of care and patient burden. Administration of ketanserin, a serotonin 2 receptor (5HT2R) antagonist, prior to psilocybin attenuates the psychedelic side effects. But whether ketanserin would also block the antidepressant effect is unknown. I sought to test the hypothesis that psilocybin has an antidepressant-like effect in rodents independent of the 5HT2R. To this end, I have demonstrated that psilocybin has a rapid antidepressant effect in anhedonic mice and increases synaptic strength in hippocampus following chronic stress. Prior administration of ketanserin blocks neither psilocybin’s antidepressant-like effect nor the increase in synaptic strength. In vitro electrophysiology experiments failed to show acute effects of psilocin, possibly due to psilocin’s rapid oxidation. While the antidepressant mechanism of action of psilocybin remains unknown, my data suggest the 5HT2R may not be necessary for the antidepressant effects.
dc.subjectantidepressants
dc.subjectdepressionen_US
dc.subjectpsychedelicsen_US
dc.subject.meshAnhedoniaen_US
dc.subject.meshAntidepressive Agentsen_US
dc.subject.meshDepressive Disorder, Majoren_US
dc.subject.meshHallucinogensen_US
dc.subject.meshPsilocybinen_US
dc.subject.meshRewarden_US
dc.titlePsilocybin as a Rapid Acting Antidepressant: Are Hallucinations Necessary?en_US
dc.typedissertationen_US
dc.date.updated2021-01-28T20:06:50Z
dc.language.rfc3066en
dc.contributor.advisorThompson, Scott M., Ph.D.
dc.contributor.orcid0000-0001-8076-1413en_US
refterms.dateFOA2021-02-05T16:24:21Z


Files in this item

Thumbnail
Name:
Hesselgrave_umaryland_0373D_11 ...
Size:
1.733Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record